ReviewEuropean journal of clinical pharmacology2011
The role of population PK-PD modelling in paediatric clinical research.
Review in European journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Utilization of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacoepidemiological Studies: A Systematic Review on Antiarrhythmic and Glucose-Lowering Medicines.Frontiers in pharmacology · 2022Pooled it
- Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.Antimicrobial agents and chemotherapy · 2019Pooled it
- Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance.Clinical pharmacokinetics · 2021Trial
- Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity.Pharmacology research & perspectives · 2020Trial
- Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia.Clinical pharmacokinetics · 2019Trial
- Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.British journal of clinical pharmacology · 2018Trial
- Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.Journal of pharmacokinetics and pharmacodynamics · 2016Trial
- Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.British journal of clinical pharmacology · 2015Trial
- Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants.European journal of clinical pharmacology · 2015Trial
- Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis.Clinical pharmacokinetics · 2015 · on this mapTrial
- Trial
- Evidence-based morphine dosing for postoperative neonates and infants.Clinical pharmacokinetics · 2014Trial
- Plasma Lidocaine Concentrations During Intravenous Lidocaine Infusion Therapy in the Pediatric Population-A Scoping Review.Paediatric anaesthesia · 2026Article
- The 95% CDIRAs, a Credible Interval Based Method to Capture Uncertainty in Population Modeling: Pharmacokinetics Versus Sum of Exponentials Case Study.CPT: pharmacometrics & systems pharmacology · 2026Article
- Advancing Pediatric Dose Scaling: Strategies, Modeling Approaches, and Clinical Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Population pharmacokinetic modeling and simulation-informed ceftazidime dosing in Chinese neonates using quantitative dried blood spot micro-sampling.Antimicrobial agents and chemotherapy · 2026Article
- Evaluation of drugs and risk factors requiring therapeutic drug monitoring in the Neonatal Intensive Care Unit: a retrospective study.BMC pediatrics · 2026Article
- Optimizing Oligonucleotide Therapeutics: A Model-Informed Drug Development Perspective.Clinical and translational science · 2026Review
- External Pharmacokinetic Model Evaluation of Caffeine in Critically Ill Neonates With Heart Disease Using Data Collected From a Pragmatic Platform Trial.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Investigation of Monoclonal Antibody Pharmacokinetics in Pediatric Population and Characterization Using a Platform PBPK Model.The AAPS journal · 2026Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children differ from adults in their response to drugs. While this may be the result of changes in dose exposure (pharmacokinetics [PK]) and/or exposure response (pharmacodynamics [PD]) relationships, the magnitude of these changes may not be solely reflected by differences in body weight. As a consequence, dosing recommendations empirically derived from adults dosing regimens using linear extrapolations based on body weight, can result in therapeutic failure, occurrence of adverse effect or even fatalities. In order to define rational, patient-tailored dosing schemes, population PK-PD studies in children are needed. For the analysis of the data, population modelling using non-linear mixed effect modelling is the preferred tool since this approach allows for the analysis of sparse and unbalanced datasets. Additionally, it permits the exploration of the influence of different covariates such as body weight and age to explain the variability in drug response. Finally, using this approach, these PK-PD studies can be designed in the most efficient manner in order to obtain the maximum information on the PK-PD parameters with the highest precision. Once a population PK-PD model is developed, internal and external validations should be performed. If the model performs well in these validation procedures, model simulations can be used to define a dosing regimen, which in turn needs to be tested and challenged in a prospective clinical trial. This methodology will improve the efficacy/safety balance of dosing guidelines, which will be of benefit to the individual child.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.